The Kiplinger 25 is a list of our favorite no-load mutual funds. We favor funds run by seasoned managers who take a long view and have proved themselves able to weather many a storm.

Five months after giving up on its lead drug Betalutin for follicular lymphoma, Nordic Nanovector has charted a course forward via a merger with fellow Norwegian biotech APIM Therapeutics. The ...

Nordic Nanovector's plan to emerge from its current troubles by merging with APIM Therapeutics has hit an insurmountable hurdle – in the shape of its own shareholders. The troubled Norwegian ...